{"id":49191,"date":"2025-11-27T21:48:08","date_gmt":"2025-11-27T13:48:08","guid":{"rendered":"https:\/\/flcube.com\/?p=49191"},"modified":"2025-11-27T21:48:09","modified_gmt":"2025-11-27T13:48:09","slug":"boan-biotechs-boyoujing-aflibercept-wins-nmpa-approval-for-retinal-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49191","title":{"rendered":"Boan Biotech&#8217;s Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases"},"content":{"rendered":"\n<p><strong>Shandong Boan Biotechnology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6955:HKG\">HKG: 6955<\/a>) announced that its self\u2011developed <strong>Aflibercept Intravitreal Injection (Boyoujing)<\/strong> received <strong>National Medical Products Administration (NMPA) marketing approval<\/strong> for <strong>neovascular (wet) age\u2011related macular degeneration (nAMD)<\/strong> and <strong>diabetic macular edema (DME)<\/strong> in adults. Boan Biotech will partner with <strong>Ocumension Therapeutics<\/strong> for mainland China commercialization and has authorized <strong>Shenzhen Kexing Pharmaceutical<\/strong> for exclusive sales in select global territories.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Boyoujing (Aflibercept Intravitreal Injection)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Shandong Boan Biotechnology Co., Ltd. (6955.HK)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Marketing authorization<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>nAMD and DME in adults<\/td><\/tr><tr><td><strong>Biosimilar Reference<\/strong><\/td><td>Bayer\u2019s EYLEA (aflibercept)<\/td><\/tr><tr><td><strong>China Partner<\/strong><\/td><td>Ocumension Therapeutics (commercialization)<\/td><\/tr><tr><td><strong>Global Partner<\/strong><\/td><td>Shenzhen Kexing Pharmaceutical (exclusive sales, ex\u2011China\/EU\/UK\/US\/Japan)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Humanized fusion protein binding <strong>VEGF\u2011A, VEGF\u2011B, and Placental Growth Factor (PlGF)<\/strong> \u2013 broader target range than anti\u2011VEGF monoclonal antibodies<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> <strong>Biosimilar to EYLEA<\/strong> with comparable efficacy\/safety profile; offers <strong>cost advantage<\/strong> vs. originator in price\u2011sensitive China market<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Intravitreal injection; well\u2011established safety profile from reference product<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China nAMD Patients<\/strong><\/td><td>~<strong>3.5\u202fmillion<\/strong> (2024)<\/td><\/tr><tr><td><strong>China DME Patients<\/strong><\/td><td>~<strong>4.2\u202fmillion<\/strong> (2024)<\/td><\/tr><tr><td><strong>Anti\u2011VEGF Market Size (China)<\/strong><\/td><td>\u00a518\u202fbillion (US$2.5\u202fbillion)<\/td><\/tr><tr><td><strong>Growth CAGR<\/strong><\/td><td>15% (2024\u20112030)<\/td><\/tr><tr><td><strong>Peak Sales Forecast (Boyoujing)<\/strong><\/td><td><strong>\u00a53.5\u20114.5\u202fbillion<\/strong> (~US$480\u2011610\u202fmillion) by 2032<\/td><\/tr><tr><td><strong>Market Share Target<\/strong><\/td><td>20\u201125% of aflibercept\u2011class market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Landscape:<\/strong> Dominated by <strong>Bayer\u2019s EYLEA<\/strong> (~60% share) and <strong>Roche\u2019s Lucentis<\/strong> (~25%); Boyoujing\u2019s biosimilar pricing (30\u201140% discount) and Ocumension\u2019s <strong>ophthalmology specialist network<\/strong> (covers <strong>8,000+ hospitals<\/strong>) provide strong market access<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Kexing partnership covers <strong>Latin America, Southeast Asia, Middle East, Africa<\/strong> \u2013 markets with <strong>limited anti\u2011VEGF access<\/strong> and high diabetes burden<\/li>\n\n\n\n<li><strong>Reimbursement Path:<\/strong> Likely <strong>automatic NRDL inclusion<\/strong> under China\u2019s biosimilar policy; pricing expected at <strong>\u00a58,000\u201110,000 per dose<\/strong> vs. EYLEA\u2019s \u00a512,000<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Boyoujing\u2019s commercial launch, market penetration, and partnership execution. Actual results may differ materially due to risks including competitive responses, reimbursement negotiations, and manufacturing scale\u2011up.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that its self\u2011developed Aflibercept Intravitreal Injection (Boyoujing)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49192,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[43,220,1024,44,15],"class_list":["post-49191","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biosimilars","tag-boan-biotechnology","tag-hkg-6955","tag-ophthalmology","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boan Biotech&#039;s Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that its self\u2011developed Aflibercept Intravitreal Injection (Boyoujing) received National Medical Products Administration (NMPA) marketing approval for neovascular (wet) age\u2011related macular degeneration (nAMD) and diabetic macular edema (DME) in adults. Boan Biotech will partner with Ocumension Therapeutics for mainland China commercialization and has authorized Shenzhen Kexing Pharmaceutical for exclusive sales in select global territories.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49191\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boan Biotech&#039;s Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases\" \/>\n<meta property=\"og:description\" content=\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that its self\u2011developed Aflibercept Intravitreal Injection (Boyoujing) received National Medical Products Administration (NMPA) marketing approval for neovascular (wet) age\u2011related macular degeneration (nAMD) and diabetic macular edema (DME) in adults. Boan Biotech will partner with Ocumension Therapeutics for mainland China commercialization and has authorized Shenzhen Kexing Pharmaceutical for exclusive sales in select global territories.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49191\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-27T13:48:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-27T13:48:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2707.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49191#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49191\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boan Biotech&#8217;s Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases\",\"datePublished\":\"2025-11-27T13:48:08+00:00\",\"dateModified\":\"2025-11-27T13:48:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49191\"},\"wordCount\":328,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49191#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2707.webp\",\"keywords\":[\"Biosimilars\",\"Boan Biotechnology\",\"HKG: 6955\",\"Ophthalmology\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49191#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49191\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49191\",\"name\":\"Boan Biotech's Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49191#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49191#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2707.webp\",\"datePublished\":\"2025-11-27T13:48:08+00:00\",\"dateModified\":\"2025-11-27T13:48:09+00:00\",\"description\":\"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that its self\u2011developed Aflibercept Intravitreal Injection (Boyoujing) received National Medical Products Administration (NMPA) marketing approval for neovascular (wet) age\u2011related macular degeneration (nAMD) and diabetic macular edema (DME) in adults. Boan Biotech will partner with Ocumension Therapeutics for mainland China commercialization and has authorized Shenzhen Kexing Pharmaceutical for exclusive sales in select global territories.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49191#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49191\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49191#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2707.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2707.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boan Biotech's Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49191#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boan Biotech&#8217;s Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boan Biotech's Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that its self\u2011developed Aflibercept Intravitreal Injection (Boyoujing) received National Medical Products Administration (NMPA) marketing approval for neovascular (wet) age\u2011related macular degeneration (nAMD) and diabetic macular edema (DME) in adults. Boan Biotech will partner with Ocumension Therapeutics for mainland China commercialization and has authorized Shenzhen Kexing Pharmaceutical for exclusive sales in select global territories.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49191","og_locale":"en_US","og_type":"article","og_title":"Boan Biotech's Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases","og_description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that its self\u2011developed Aflibercept Intravitreal Injection (Boyoujing) received National Medical Products Administration (NMPA) marketing approval for neovascular (wet) age\u2011related macular degeneration (nAMD) and diabetic macular edema (DME) in adults. Boan Biotech will partner with Ocumension Therapeutics for mainland China commercialization and has authorized Shenzhen Kexing Pharmaceutical for exclusive sales in select global territories.","og_url":"https:\/\/flcube.com\/?p=49191","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-27T13:48:08+00:00","article_modified_time":"2025-11-27T13:48:09+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2707.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49191#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49191"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boan Biotech&#8217;s Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases","datePublished":"2025-11-27T13:48:08+00:00","dateModified":"2025-11-27T13:48:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49191"},"wordCount":328,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49191#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2707.webp","keywords":["Biosimilars","Boan Biotechnology","HKG: 6955","Ophthalmology","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49191#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49191","url":"https:\/\/flcube.com\/?p=49191","name":"Boan Biotech's Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49191#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49191#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2707.webp","datePublished":"2025-11-27T13:48:08+00:00","dateModified":"2025-11-27T13:48:09+00:00","description":"Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that its self\u2011developed Aflibercept Intravitreal Injection (Boyoujing) received National Medical Products Administration (NMPA) marketing approval for neovascular (wet) age\u2011related macular degeneration (nAMD) and diabetic macular edema (DME) in adults. Boan Biotech will partner with Ocumension Therapeutics for mainland China commercialization and has authorized Shenzhen Kexing Pharmaceutical for exclusive sales in select global territories.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49191#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49191"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49191#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2707.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2707.webp","width":1080,"height":608,"caption":"Boan Biotech's Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49191#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boan Biotech&#8217;s Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2707.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49191"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49191\/revisions"}],"predecessor-version":[{"id":49193,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49191\/revisions\/49193"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49192"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}